P&S Market Research - A market research firm

Press Journals

Synovial Sarcoma to Witness Major Collaborations in the Coming Years

May 2017

According to a new research report “Synovial Sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Synovial sarcoma currently exhibits a pipeline with 22 drug candidates.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis

Synovial sarcoma pipeline in 2017

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.


New innovating technologies offer development of promising drugs

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma.  ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

Novel upcoming therapies and promising drug targets for treatment of Synovial sarcoma

The combination of novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Major companies collaborate for the development of Synovial Sarcoma Pipeline

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

Synovial sarcoma Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company